







































Total vascular resistance, augmentation index,
and augmentation pressure increase in patients
with peripheral artery disease
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Abstract
Peripheral arterial disease (PAD) is one of major vascular diseases which frequently coexists with coronary arterial disease and
cerebrovascular disease. The patients with PAD have a poor prognosis when it progresses. A new blood pressure testing device
enables to simultaneously measure brachial blood pressure (BP), central BP, and several vascular parameters, with easy and non-
invasive, in a short time. Here, we aimed to evaluate these arterial stiffness parameters in patients with PAD.
In this study, 243 consecutive patients who were suspected of having PAD and referred to our hospital from September 2016 to
June 2019, were registered. Several parameters, such as brachial BP, central BP, aortic pulse wave velocity (aPWV), total vascular
resistance (TVR), augmentation index (AI) and augmentation pressure (AP), were determined by Mobil-O-Graph. Ankle-brachial
pressure index (ABI) was used to define PAD (ABI0.9 as PAD). The relationship between PAD and central BP, aPWV, TVR, AI, or
AP were investigated.
One hundred sixty-two patients (67%) were categorized as the PAD group and 81 patients (33%) as the non-PAD group.
In the PAD group, the systolic brachial BP and central systolic BP were significantly higher than those in the non-PAD group
(138±24mmHg vs 131±19mmHg, P< .05, 125±22mmHg vs 119±18 mmHg, P< .05, respectively). TVR, AI, and AP were
significantly higher in the PAD group (1785±379dyns/cm5 vs 1661±317dyns/cm5, P< .05, 26.2±13.0% vs 22.2±13.3%,
P< .05, 13.5±9.4mmHg vs 10.7±7.2mmHg, P< .05, respectively). No significant differences in diastolic BP, central diastolic BP,
and aPWV were found between the groups. Multivariate logistic regression analysis revealed that PAD was significantly associated
with TVR, AI, and AP (P< .05, respectively).
TVR/AP/AI were significantly higher in the PAD group than in the non-PAD group.
Abbreviations: ABI= ankle-brachial pressure index, AI= augmentation index, AP= augmentation pressure, aPWV= aortic pulse
wave velocity, BP = blood pressure, bPP = brachial pulse pressure, bSBP = brachial systolic blood pressure, cPP = central pulse
pressure, cSBP= central systolic blood pressure, PAD= peripheral arterial disease, PWV= pulse wave velocity, TVR= total vascular
resistance.
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In recent years, the increase of lifestyle-related diseases largely
associated with metabolic syndrome has been remarkable.[1–3]
Along with this increment, arteriosclerotic diseases are also
increasing.[1,2] Atherosclerosis can occur in blood vessels
throughout the body. Peripheral vascular disease (PAD) is a
condition in which arteriosclerosis mainly occurs in blood vessels
of the limbs and is usually determined by ankle-brachial pressure
index (ABI).[1,2,4,5] The main causes of PAD are lifestyle-related
diseases, such as hypertension, diabetes, dyslipidemia, chronic
kidney disease, smoking, and obesity. It is well known that the
cause of increased mortality when PAD progresses to foot
amputation.[1,4]
Arterial stiffness can be assessed by a variety of methods.
Increase of arterial stiffness is associated with higher risk for the
development of arteriosclerosis and recognized as a prognostic
marker beyond standard risk factors. Currently, arterial stiffness
is able to be measured non-invasively and reproducibly.[6–9]
To date, to evaluate vascular dysfunction, an early stage of
arteriosclerosis, several devises have been developed. Pulse wave
velocity (PWV) is widely used in clinical practice as a parameter
for arterial stiffness.[10,11] Flow mediated dilatation represents
vascular endothelial function.[12,13] Cardio-ankle vascular index
is used for estimating the extent of arterial stiffness and
atherosclerosis.[14–16] Augmentation index is used as a surrogate
measure of arterial stiffness.[17–19] Multiple measurements for
these parameters for evaluation of vascular function provide a
clue of arteriosclerosis. These parameters are widely used in
clinical practice worldwide, however, the accuracy of these
methods is unsatisfactory especially in the patients with PAD.
Vascular catheterization can evaluate hemodynamics in patients
with PAD, such as vascular resistance and arterial central blood
pressure, but invasive. Recently, Mobil-O-graph has been
developed and it enables non-invasive and simultaneous
measurement of several vascular parameters with shorter
procedure duration.[20,21] So far, the evaluation of PAD using
Mobil-O-graph has not been reported.
Therefore, in this study, we aimed to examine the association
of several parameters determined by Mobil-O-graph, such as
central blood pressure, brachial blood pressure, aortic PWV
(aPWV), total vascular resistance (TVR), augmentation pressure
(AP), and augmentation index (AI), with PAD. Among them,
TVR, AP, and AI were found to have a significant association
with PAD.
2. Materials and methods
2.1. Study design
This was a single-center, and cross-sectional observational study.
2.2. Participants
The participants were recruited from outpatients who were
suspected of having PAD and referred to our hospital from
September 2016 to June 2019, and who were 20years old and
over, and obtained informed consent of the present study.
Patients who disagreed to participate in this study were excluded.
Based on physician’s charts, characteristics of each participant
was evaluated, including age, sex, body mass index, smoking,
diabetes mellitus, hypertension, dyslipidemia, chronic kidney
disease, ischemic heart disease, cerebral infarction, and medi-
cations. Lab data were collected as following: serum creatinine,
calcium, phosphorus, hemoglobin, fasting plasma glucose, total
cholesterol, triglycerides, high-density lipoprotein cholesterol,
and low-density lipoprotein cholesterol.
Participants received a test under fasting, alcohol-free, and
non-smoking, or refraining smoking at least 12hours condition.
The definition of disease is as follows; diabetes mellitus was
defined by receiving medication for diabetes mellitus or fulfilling
the diagnostic criteria: postprandial plasma glucose levels ≥200
mg/dL and/or HbA1c ≥6.5%. Dyslipidemia was defined by
receiving medication for dyslipidemia or fulfilling the diagnostic
criteria: LDL-cholesterol ≥140mg/dL, HDL-cholesterol <40mg/
dL, triglycerides ≥150mg/dL. Chronic kidney disease was
defined as eGFR <60mL/min/1.73m2 or urinary protein≥±.
In the dipstick test, ± is considered equal to 0.15g/gCr.
Hypertension was defined by receiving anti-hypertensive
agents or ≥140/90mmHg. Ischemic heart disease was defined
as symptomatic and having history of percutaneous coronary
intervention treatment and/or surgical operation of coronary
artery bypass grafting. Cerebral infarction was defined as
symptomatic and requiring hospital treatment. Smoking included
both current and past habitat of smoking.
2.3. Evaluation of ankle-brachial pressure index
ABI was determined with BP-203RPE II form (FUKUDACOLIN,
Japan) or VaSera VS-1500A (FUKUDA DENSHI, Japan),
followed manufactural instruction. In brief, ABI was measured
after resting in a supine position for 5minutes in a temperature-
controlled (22–25 °C) room. Blood pressure was measured using
oscillometric method. Oscillometry was based on the assumption
that maximum oscillations occurring in the vessel in slow cuff
deflation correspond to mean arterial pressure from which
mathematical formulas can deduct the systolic and diastolic
blood pressure.[22,23] Cuffs were applied to both upper arms and
ankles. ABI was calculated dividing the ankle SBP in each leg by
the higher SBP of upper arm. The lower ABI value was used as
representative ABI of each participant.
2.4. Definition of the peripheral artery disease
PAD was defined as ABI 0.9.
2.5. Evaluation measurements of vascular parameter
Several vascular parameters were measured using Mobil-O-
Graph (IEM, Stolberg, Germany); brachial systolic blood
pressure (bSBP), brachial diastolic blood pressure, brachial pulse
pressure (bPP), central systolic blood pressure (cSBP), central
diastolic blood pressure, central pulse pressure (cPP), aPWV,
TVR, AP, AI, stroke volume, cardiac output, and cardiac index.
Each participant laid on the bed in a spine position for >5
minutes in a quiet and temperature-controlled room, then, the
measurement was performed in accordance with the manufac-
turer instruction.
The Mobil-O-Graph had an inbuilt ARCSolver (Austrian
Institute of Technology, Vienna, Austria). After brachial BP was
measured, the cuff was instantly inflated, and brachial artery
pressure waves were recorded, holding the diastolic BP level for
10seconds. Brachial artery pressure wave was digitized with a
high-fidelity pressure sensor connected to a 12-bit A/D converter.
Central AI and AP were calculated using a generalized transfer
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function. The ARCSolver transfer function includes an algorithm
for checking the signal quality. We analyzed only excellent or
good-quality results, that is, >80% or >50% of signals used for
the transfer function, respectively.[24]
This running 1st pulse wave gets reflected from distal
branching point of aortic wall and generates 2nd reflected wave.
Arterial stiffness mainly determines the morphology of reflected
2nd wave. AIX and PWV were obtained with the help of
algorithm and mathematical model in the inbuilt software by
using amplitude and time difference of 1st and 2nd wave.[25]
2.6. Ethics
This study followed the Declaration of Helsinki (seventh revision,
2013) on medical protocol and ethics. Informed consent was
obtained from all participants. The ethics committee of the
Institutional Review Board in Okayama University Hospital
approved the protocol (Ken1609-029).
2.7. Statistics
All data are presented as the mean± standard deviation or
number (%). Differences between the 2 groups were examined
by a student t test or chi-squared test where appropriate.
Multivariate logistic regression analyses were performed to
investigate the association of TVR, AP, and AI with PAD.
Statistical significance was defined as P< .05. All data were
analyzed using JMP (version 13.0, SAS Institute Inc., Cary, NC).
3. Results
3.1. Characteristics of the participants
Characteristics of the participants are shown in Table 1. A total of
243 participants were enrolled. One hundred sixty-two patients
(67%) were categorized as the PAD group and 81 patients (33%)
as the non-PAD group. No significant differences were found in
baseline characteristics between the groups, except for smoking
habitat (P= .0272) and usage of antiplatelet drugs (P= .0007).
3.2. Vascular parameters of participants
Vascular parameters are shown in Table 2. In the PAD group, the
bSBP, cSBP, bPP, and cPP were significantly higher than those in
the non-PAD group (138±24mmHg vs 131±19mmHg, P
= .0129, 125±22mmHg vs 119±18mmHg, P= .0295, 57±17
mmHg vs 51±12mmHg, P= .0047, 42±15mmHg vs 38±11
mmHg, P= .0260, respectively). TVR, AI, and AP were
significantly higher in the PAD group (1785±379dyns/cm5 vs
1661±317dyns/cm5, P= .0079, 26.2±13.0% vs 22.2±13.3%,
P= .0284, 13.5±9.4mmHg vs 10.7±7.2mmHg, P= .0103,
respectively). No significant differences in brachial diastolic
Table 1
Characteristic of the study participants.
Characteristic n=243 PAD (n=162) Non-PAD (n=81) P value
Age, yr 71±10 72±11 70±10 .5585
Sex (male, %) 165 (68) 108 (65) 54 (69) .2452
Body mass index, kg/m2 22.5±4.0 22.2±3.8 23.0±4.3 .1794
Smoking (%) 183 (75) 129 (80) 54 (67) .0272
Diabetes mellitus (%) 141 (58) 97 (60) 44 (54) .4081
Hypertension (%) 209 (86) 141 (87) 68 (84) .5132
Dyslipidemia (%) 176 (72) 121 (75) 55 (68) .2642
Chronic kidney disease (%) 155 (64) 108 (67) 47 (58) .1864
Ischemic heart disease (%) 75 (31) 51 (31) 24 (30) .7683
Cerebral infarction (%) 36 (15) 26 (16) 10 (12) .4436
Medications
Antiplatelet agent (%) 172 (71) 126 (78) 46 (57) .0007
Statin (%) 123 (51) 81 (50) 42 (52) .7855
ACEI (%) 33 (14) 22 (14) 11 (14) 1.0000
ARB (%) 109 (45) 77 (48) 32 (40) .2358
b-blocker (%) 94 (39) 66 (41) 28 (35) .3517
CCB (%) 134 (55) 88 (54) 46 (57) .7152
Diuretics (%) 65 (27) 45 (28) 20 (25) .6084
Anticoagulant (%) 49 (20) 28 (17) 21 (26) .1135
Lab data
Creatinine, mg/dL 2.16±3.02 2.27±3.10 1.93±2.87 .3987
Calcium, mg/dL 9.1±0.6 9.1±0.6 9.0±0.48 .3134
Phosphorus, mg/dL 3.8±1.0 3.8±1.0 3.9±1.2 .6177
Hemoglobin, g/dL 12.5±1.9 12.6±1.9 12.3±1.9 .3144
Fasting plasma glucose, mg/dL 115±35 114±38 117±27 .5946
Total cholesterol, mg/dL 117±36 178±37 176±36 .7477
Triglycerides, mg/dL 155±121 150±102 167±155 .4253
High-density lipoprotein cholesterol, mg/dL 53±16 53±17 53±15 .8750
Low-density lipoprotein cholesterol, mg/dL 101±31 100±31 102±32 .7022
Data are presented as mean±SD.
ACEI=angiotensin converting enzyme inhibitor, ARB= angiotensin II receptor blocker, CCB= calcium channel blocker, PAD=peripheral artery disease.
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blood pressure, central diastolic blood pressure, aPWV, stroke
volume, cardiac output, nor cardiac index, between the groups.
3.3. Multivariate logistic regression analyses for TVR, AP,
and AI
Multivariate logistic regression analyses were performed to
investigate the association of PAD with TVR, AP, and AI. As
shown in Table 3 model 1, the results demonstrated that the PAD
was significantly associated with TVR (OR: 8.2003, 95% CI:
1.5084–49.5750, P= .0178), as well as AP and AI (P= .0316,
P= .0327, respectively) adjusted with age, sex, and body mass
index. These significant association remained adjusted with
model 1 covariates plus smoking (Table 3, model 2). In model 3,
further adjusted by classical risk factors for cardiovascular
diseases, the association between PAD and TVR still
remained significant (OR: 5.7677, 95% CI: 1.0028–36.8522,
P= .0496).
4. Discussion
In this study, we found that bSBP, cSBP, bPP, and cPP in the PAD
groupwere significantly higher than those in the non-PAD group.
In addition, TVR, AI, andAPwere significantly higher in the PAD
group compared with non-PAD group. Moreover, a multivariate
logistic regression analyses demonstrated that PAD was
significantly associated with TVR, AP, and AI adjusted with
established multiple risk factors.
TVR basically presents resistance to blood flow that occurs in
blood vessels. The definition of TVR is calculated as follows;
TVR is equal to mean arterial BP divided by cardiac output. TVR
is significantly higher in women than in men.[26] Especially,
elevated TVRwas observed in older women.[26] It is also reported
that high TVR is associated with mortality, heart failure, and
CVD events.[25] Thus, increased TVR may further enhance the
accumulated risk for cardiovascular disease. As expected, in the
current study, higher TVR is associatedwith the presence of PAD.
This might be simply because the risks for PAD are common
compared with other heart and vascular diseases such as heart
failure, ischemic heart disease, and stroke. Indeed, the patients
with PAD are known to have high CAD risk.[1,27] The other
reason is that the mean arterial BP elevated in patients with
arterial sclerosis and several patients with PAD have a low
cardiac output due to CAD. Consequently, TVRmay increase by
reflecting peripheral arterial stenosis and low cardiac output.
Therefore, TVR well-represents the vascular condition of
atherosclerosis throughout the body.
AP represents changes in central hemodynamics and pressure
wave characteristics resulting from increased aortic wall
stiffening and aortic remodeling.[11] The central AP determined
by the Mobil-O-Graph was reported to be associated with age
and sex in the European community-based population.[28]
Higher central AP is associated with increased risk of develop-
ment of CAD in younger and middle-aged men.[28] Thus, AP may
reflect the accumulation of cardiovascular risks in association
with aortic wall stiffening. In the current study, AP in the PAD
group is significantly higher than that in the non-PAD group.
aPWV is also known as one of the surrogate markers for aortic
stiffness.[25] However, our study showed no difference in aPWV
between the PAD group and the non-PAD groups. This result
suggests that aPWV may not reflect the peripheral vascular
Table 3
Multivariate analysis for TVR, AP, and AI.
Odds ratio 95% CI P
TVR
Model 1 8.2003 1.5084–49.5750 .0178
Model 2 7.4557 1.3218–46.7984 .0267
Model 3 5.7677 1.0028–36.8522 .0496
AP
Model 1 5.5435 1.1632–26.4088 .0316
Model 2 5.1042 1.1002–27.0629 .0451
Model 3 4.0939 0.8490–22.4330 .0901
AI
Model 1 4.8282 1.1504–20.8968 .0327
Model 2 4.8889 1.1218–21.9658 .0359
Model 3 4.3908 0.9861–20.0614 .0534
Model 1; Adjusted for age, sex, and body mass index.
Model 2; Adjusted for Model 1 covariates plus smoking.
Model 3; Adjusted for Model 2 covariates plus diabetes mellitus, hypertension, dyslipidemia, and
chronic kidney disease.




n=243 PAD (n=162) Non-PAD (n=81) P value
bSBP, mmHg 136±23 138±24 131±19 .0129
bDBP, mmHg 81±12 81±13 80±12 .3602
bPP, mmHg 55±16 57±17 51±12 .0047
cSBP, mmHg 123±21 125±22 119±18 .0295
cDBP, mmHg 83±13 83±13 81±12 .2937
cPP, mmHg 41±14 42±15 38±11 .0260
aPWV, m/s 10.8±2.0 10.9±2 10.5±2 .0694
Total vascular resistance, dyn s/cm5 1744±364 1785±379 1661±317 .0079
Augmentation index (%) 24.9±13.2 26.2±13 22.2±13.3 .0284
Augmentation pressure, mmHg 12.6±8.8 13.5±9.4 10.7±7.2 .0103
Stroke volume, mL 73±14 72±13 75±15 .0826
Cardiac output, L/min 5.0±0.9 4.9±0.9 5.1±0.9 .2093
Cardiac index, L/min/m2 3.1±0.7 3.1±0.7 3.1±0.7 .9649
aPWV= aortic pulse wave velocity, bDBP=brachial diastolic blood pressure, bPP=brachial pulse pressure, bSBP=brachial systolic blood pressure, cCBP= central systolic blood pressure, cDBP=central
diastolic blood pressure, cPP= central pulse pressure, PAD=peripheral artery disease.
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condition but represents central vascular condition. AP may be a
better way to evaluate arterial stiffness than aPWV.
AI presents an indirect measurement of arterial stiffness.[29,30]
Several papers have reported the clinical significance of AI. An
increase in central AI is related to a risk of increase of
cardiovascular events and all-cause mortality.[11,31] AI can
predict clinical cardiovascular events independent of peripheral
pressures.[11] AI is recognized as one of useful markers of arterial
stiffness in patients with PAD.[32] AI is higher in patients with
PAD as compared with control patients.[33] In consistent with
these studies, AI in the PAD group is significantly higher than that
in non-PAD group in the present study, although all participants
were referred to our institute to be suspicious for PAD. This result
suggests that higher value of AI may be linked to vascular stenosis
or occlusion in the peripheral artery. In this sense, AI can
represent from mild to severe vascular condition.
Several limitations in this study are noted. Firstly, this study
was conducted in a single-institution study, with a small number
of participants. Secondly, since all participants were referred to
our hospital to be suspicious for PAD, the background of all
participants were bias. That is, all participants in this study had,
at least one or more risks for atherosclerosis. No healthy person
was examined. Future study will be required to conduct a study in
the general population. Third, since the current studywas a cross-
sectional observation study, the effect of the interventional
treatments for PAD on the changes in these parameters were not
clarified. Fourth, in this study, PAD was defined only by ABI
value, however, ABI alone cannot provide a precise diagnosis of
PAD in clinical setting. Fifth, in the present study, ABI value was
determined by the oscillometric method, not by the doppler
method. Future study will be required to further confirm whether
TVR/AP/AI are valuable markers for PAD.
5. Conclusions
TVR, AP, and AI were significantly higher in the PAD group than
in the non-PAD group. Non-invasive, easy, and reproducible tool
is desirable to assess arterial stiffness.
Acknowledgments
The authors would like to thank Dr. Hiroaki Otsuka and Dr.
Kentaro Ejiri from Department of Cardiovascular Medicine,
Okayama University Graduate School of Medicine, Dentistry
and Pharmaceutical Sciences for patient recruitments, and Dr.
Shugo Okamoto, Dr. Yasuhiro Onishi, Dr. Mariko Tsuchida-
Nishiwaki, Dr. Natsumi Matsuoka-Uchiyama, Dr. Nozomu
Otaka, Dr. Yuki Kakio, Dr. Hidemi Takeuchi, and Dr. Yoshiko
Hada from Department of Nephrology, Rheumatology, Endo-
crinology and Metabolism, Okayama University Graduate
School of Medicine, Dentistry and Pharmaceutical Sciences for
helpful comment.
Author contributions
Conceptualization: Rika Takemoto, Haruhito A. Uchida.
Data curation: Rika Takemoto.
Formal analysis: Rika Takemoto, Haruhito A. Uchida.
Investigation: Rika Takemoto, Haruhito A. Uchida, Hironobu
Toda.
Writing – original draft: Rika Takemoto.
Writing – review & editing: Haruhito A. Uchida, Hironobu
Toda, Ken Okada, Fumio Otsuka, Hiroshi Ito, Jun Wada.
References
[1] Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for
the management of peripheral arterial disease (TASC II). J Vasc Surg
2007;45(suppl):S5–67.
[2] Kithcart AP, Beckman JA. ACC/AHA versus ESC guidelines for
diagnosis and management of peripheral artery disease: JACC guideline
comparison. J Am Coll Cardiol 2018;72:2789–801.
[3] Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the
Diagnosis and Treatment of Peripheral Arterial Diseases, in collabora-
tion with the European Society for Vascular Surgery (ESVS): document
covering atherosclerotic disease of extracranial carotid and vertebral,
mesenteric, renal, upper and lower extremity arteriesEndorsed by: the
European Stroke Organization (ESO)The Task Force for the Diagnosis
and Treatment of Peripheral Arterial Diseases of the European Society of
Cardiology (ESC) and of the European Society for Vascular Surgery
(ESVS). Eur Heart J 2018;39:763–816.
[4] Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016AHA/ACC
guideline on the management of patients with lower extremity peripheral
artery disease: executive summary: a report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines. J Am Coll Cardiol 2017;69:1465–508.
[5] Hiatt WR. Medical treatment of peripheral arterial disease and
claudication. N Engl J Med 2001;344:1608–21.
[6] Gajdova J, Karasek D, Goldmannova D, et al. Pulse wave analysis and
diabetes mellitus. A systematic review. Biomed Pap Med Fac Univ
Palacky Olomouc Czech Repub 2017;161:223–33.
[7] Mendes-Pinto D, Rodrigues-Machado MDG. Applications of arterial
stiffness markers in peripheral arterial disease. J Vasc Bras 2019;18:
e20180093.
[8] Piskorski J, Krauze T, Katulska K, et al. Contribution of arterial excess
pressure and arterial stiffness to central augmentation pressure in healthy
subjects. Int J Cardiol 2013;168:2899–900.
[9] London GM, Cohn JN. Prognostic application of arterial stiffness: task
forces. Am J Hypertens 2002;15:754–8.
[10] TanakaH,MunakataM, Kawano Y, et al. Comparison between carotid-
femoral and brachial-ankle pulse wave velocity as measures of arterial
stiffness. J Hypertens 2009;27:2022–7.
[11] Vlachopoulos C, Aznaouridis K, O’Rourke MF, Safar ME, Baou K,
Stefanadis C. Prediction of cardiovascular events and all-cause mortality
with central haemodynamics: a systematic review and meta-analysis. Eur
Heart J 2010;31:1865–71.
[12] CharakidaM,Masi S, Lüscher TF, Kastelein JJ, Deanfield JE. Assessment
of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J
2010;31:2854–61.
[13] Bellamkonda K, Williams M, Handa A, Lee R. Flow mediated dilatation
as a biomarker in vascular surgery research. J Atheroscler Thromb
2017;24:779–87.
[14] Saiki A, Ohira M, Yamaguchi T, et al. New horizons of arterial stiffness
developed using cardio-ankle vascular index (CAVI). J Atheroscler
Thromb 2020;27:732–48.
[15] Namba T, Masaki N, Takase B, Adachi T. Arterial stiffness assessed by
cardio-ankle vascular index. Int J Mol Sci 2019;20:3664.
[16] Park HE, Choi SY, Kim MK, Oh BH. Cardio-ankle vascular index
reflects coronary atherosclerosis in patients with abnormal glucose
metabolism: assessment with 256 slice multi-detector computed
tomography. J Cardiol 2012;60:372–6.
[17] Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb
DJ. The influence of heart rate on augmentation index and central arterial
pressure in humans. J Physiol 2000;525(pt 1):263–70.
[18] Wilkinson IB, Prasad K, Hall IR, et al. Increased central pulse pressure
and augmentation index in subjects with hypercholesterolemia. J Am
Coll Cardiol 2002;39:1005–11.
[19] Wilhelm B, Klein J, Friedrich C, et al. Increased arterial
augmentation and augmentation index as surrogate parameters for
arteriosclerosis in subjects with diabetes mellitus and nondiabetic
subjects with cardiovascular disease. J Diabetes Sci Technol 2007;
1:260–3.
[20] Papaioannou TG, Thymis J, Benas D, et al. Measurement of central
augmentation index by three different methods and techniques:
agreement among Arteriograph, Complior, andMobil-O-Graph devices.
J Clin Hypertens (Greenwich) 2019;21:1386–92.
[21] Grillo A, Parati G, Rovina M, et al. Short-term repeatability of
noninvasive aortic pulse wave velocity assessment: comparison between
methods and devices. Am J Hypertens 2017;31:80–8.
Takemoto et al. Medicine (2021) 100:32 www.md-journal.com
5
[22] Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility,
and clinical significance of noninvasive brachial-ankle pulse wave
velocity measurement. Hypertens Res 2002;25:359–64.
[23] Motobe K, Tomiyama H, Koji Y, et al. Cut-off value of the
ankle-brachial pressure index at which the accuracy of brachial-
ankle pulse wave velocity measurement is diminished. Circ J 2005;
69:55–60.
[24] Obayashi M, Kobayashi S, Kohno M, Nakashima T, Yano M. Cuff-
based oscillometric measurements of central hemodynamics: factors
influencing central augmentation pressure in normotensive Japanese
individuals. Pulse (Basel) 2019;6:161–8.
[25] Ghosh A, Dharmarajan A, Swain PK, Das D, Verma P, Tripathy PR.
Impact of cardiovascular factors on pulse wave velocity and total
vascular resistance in different age group patients with cardiovascular
disorders. Curr Aging Sci 2019;11:261–8.
[26] Goto T, Ohte N, Fukuta H, Wakami K, Tani T, Kimura G. Relationship
between effective arterial elastance, total vascular resistance, and
augmentation index at the ascending aorta and left ventricular diastolic
function in older women. Circ J 2013;77:123–9.
[27] Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ
Res 2015;116:1509–26.
[28] Nunan D, Wassertheurer S, Lasserson D, et al. Assessment of central
haemomodynamics from a brachial cuff in a community setting. BMC
Cardiovasc Disord 2012;12:48.
[29] Fantin F, Mattocks A, Bulpitt CJ, Banya W, Rajkumar C. Is
augmentation index a good measure of vascular stiffness in the elderly?
Age Ageing 2007;36:43–8.
[30] Kohara K, Tabara Y, Oshiumi A, Miyawaki Y, Kobayashi T, Miki T.
Radial augmentation index: a useful and easily obtainable parameter for
vascular aging. Am J Hypertens 2005;18(1 pt 2):11s–4s.
[31] Nürnberger J, Keflioglu-Scheiber A, Opazo Saez AM, Wenzel RR,
Philipp T, Schäfers RF. Augmentation index is associated with
cardiovascular risk. J Hypertens 2002;20:2407–14.
[32] HusmannM, Jacomella V, Thalhammer C, Amann-Vesti BR.Markers of
arterial stiffness in peripheral arterial disease. Vasa 2015;44:341–8.
[33] Catalano M, Scandale G, Carzaniga G, et al. Aortic augmentation index
in patients with peripheral arterial disease. J Clin Hypertens (Greenwich)
2014;16:782–7.
Takemoto et al. Medicine (2021) 100:32 Medicine
6
